

# PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 90174

Title: Treatment of Helicobacter pylori with potassium competitive acid blockers: A

systematic review and meta-analysis

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 02905308 Position: Peer Reviewer

Academic degree: MD, PhD

**Professional title:** Professor, Surgeon, Teacher

Reviewer's Country/Territory: China

Author's Country/Territory: United Kingdom

Manuscript submission date: 2023-11-26

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2023-12-13 11:22

Reviewer performed review: 2023-12-15 00:56

**Review time:** 1 Day and 13 Hours

	[Y] Grade A: Excellent [] Grade B: Very good [] Grade C:
Scientific quality	Good
	[ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ Y] Grade A: Excellent [ ] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair
this manuscript	[ ] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[ Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes [ ]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous  Conflicts-of-Interest: [ ] Yes [Y] No

### SPECIFIC COMMENTS TO AUTHORS

Helicobacter pylori infects over half the global population, causing gastrointestinal diseases like dyspepsia, gastritis, duodenitis, peptic ulcers, G-MALT lymphoma, and gastric adenocarcinoma. Eradicating H. pylori is crucial for treating and preventing these conditions. While conventional PPI-based triple therapy is effective, there's growing interest in longer acid suppression therapies. Potassium competitive acid blocker (P-CAB) triple and dual therapy are new regimens for H. pylori eradication. Initially used in Asian populations, Vonoprazan has been recently FDA-approved for H. pylori eradication. This systematic review and meta-analysis seek to assess the efficacy of regimens containing potassium competitive acid blockers in eradicating Helicobacter pylori infection. Vonoprazan-based triple therapy outperformed conventional PPI-based triple therapy in eradicating H. pylori, positioning it as a highly effective first-line regimen. Additionally, Tegoprazan-based triple therapy wass non-inferior to classical PPI triple therapy. Comments for the author: The manuscript is very interesting, and can be accepted.



# PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 90174

Title: Treatment of Helicobacter pylori with potassium competitive acid blockers: A

systematic review and meta-analysis

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03242050 Position: Editorial Board Academic degree: MD, PhD

**Professional title:** Doctor, Professor

Reviewer's Country/Territory: China

Author's Country/Territory: United Kingdom

Manuscript submission date: 2023-11-26

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2023-12-12 14:30

Reviewer performed review: 2023-12-19 14:15

**Review time:** 6 Days and 23 Hours

	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C:
Scientific quality	Good
	[ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [ Y] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of	[ ] Grade A: Excellent [ ] Grade B: Good [ Y] Grade C: Fair
this manuscript	[ ] Grade D: No creativity or innovation



Scientific significance of the conclusion in this manuscript	[ ] Grade A: Excellent [ ] Grade B: Good [ Y] Grade C: Fair [ ] Grade D: No scientific significance
Language quality	[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ Y] Major revision [ ] Rejection
Re-review	[ ]Yes [Y]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous  Conflicts-of-Interest: [ ] Yes [Y] No

# SPECIFIC COMMENTS TO AUTHORS

Thank you for the opportunity to review the manuscript titled, TREATMENT OF HELICOBACTER PYLORI WITH POTASSIUM COMPETITIVE ACID BLOCKERS: A SYSTEMATIC REVIEW AND META-ANALYSIS. This systematic review provides updated data. However, the clinical significance of this systematic review is not significant. And this study mainly focuses on Eastern populations. Perhaps changing the title of the article to "Application in Easterners" would be more appropriate.



# PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 90174

Title: Treatment of Helicobacter pylori with potassium competitive acid blockers: A

systematic review and meta-analysis

Provenance and peer review: Invited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03009411 Position: Editorial Board Academic degree: MD

**Professional title:** Associate Professor, Chief Physician

Reviewer's Country/Territory: China

Author's Country/Territory: United Kingdom

Manuscript submission date: 2023-11-26

Reviewer chosen by: Jia-Ru Fan

Reviewer accepted review: 2023-12-15 02:17

Reviewer performed review: 2023-12-23 11:53

**Review time:** 8 Days and 9 Hours

	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C:
Scientific quality	Good
	[ ] Grade D: Fair [ ] Grade E: Do not publish
Novelty of this manuscript	[ Y] Grade A: Excellent [ ] Grade B: Good [ ] Grade C: Fair [ ] Grade D: No novelty
Creativity or innovation of	[ ] Grade A: Excellent [Y] Grade B: Good [ ] Grade C: Fair
this manuscript	[ ] Grade D: No creativity or innovation



# Baishideng

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 E-mail: office@baishideng.com https://www.wjgnet.com

Scientific significance of the conclusion in this manuscript	[Y] Grade A: Excellent [] Grade B: Good [] Grade C: Fair [] Grade D: No scientific significance
Language quality	[Y] Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	[ Y] Accept (High priority) [ ] Accept (General priority) [ ] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes [ ]No
Peer-reviewer statements	Peer-Review: [Y] Anonymous [ ] Onymous  Conflicts-of-Interest: [ ] Yes [Y] No

### SPECIFIC COMMENTS TO AUTHORS

The resistance of Helicobacter pylori to antibiotics is an important reason for the failure of eradication treatment. The application of acid suppressants plays an important role in the eradication treatment of Helicobacter pylori. In recent years, the application of P-CAB in the eradication of Helicobacter pylori has received much attention. The authors assessed the efficacy of regimens containing potassium competitive acid blockers in eradicating Helicobacter pylori infection by this systematic review and meta-analysis. They found Vonoprazan-based triple therapy outperformed conventional PPI-based triple therapy in eradicating H. pylori, and Tegoprazan-based triple therapy was non-inferior to classical PPI triple therapy. This systematic review and meta-analysis can help clinicians understand the efficacy and safety of P-CAB in the treatment of Helicobacter pylori infection. "Clinicians, especially in situations where VPZ-based therapy is available and affordable, should consider it as a viable option over traditional PPI-based therapy." In addition to triple therapy, the application of P-CAB in dual therapy is also worth exploring and looking forward to. There are some spelling errors in the article, please pay attention to correction.